- Citryll’s CIT-013 could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis and organ damage due to sepsis
- Lonza’sin silicopreclinical services used to assess manufacturability and immunogenicity
- Lonza to supply final drug product in finished format for Citryll’s clinical studies
Oss, The Netherlands and Basel, Switzerland, 9 September 2019– The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. CIT-013 targets Neutrophil Extracellular Trap (NET) biology, and could offer new treatment options for a range of diseases where NETs play a role in disease pathology including autoimmune diseases like lupus, rheumatoid arthritis, vasculitis and others.
By targeting NET formation and NETs directly, CIT-013 does not broadly target inflammation or acquired immunity, but rather targets the source of autoantigens, proinflammatory as well as toxic NET components.
“With our initial funding secured we’re confident going into the next phase of the development of CIT-013. Having access to Lonza’s expertise in manufacturing and regulatory pathways will help us move to the clinic as efficiently as possible, bringing new therapeutic options to those suffering from illnesses where NETs induce the pathology including autoimmune diseases such as lupus.”, Helmuth van Es, CEO of Citryll said.
Scientific teams from the two companies have been working together to develop Citryll’s lead antibody candidate CIT-013. Using Lonza’s broad portfolio of in silicopreclinical services to assess manufacturability and immunogenicity, Citryll further improved the quality and the potency of the product.
Lonza will carry out cell line construction as well as cGMP drug substance manufacturing at its Slough, UK site. Drug product manufacturing for Citryll’s clinical supply needs will be carried out at Lonza’s recently acquired facility in Stein, Switzerland. The two companies will also work together on the regulatory requirements to secure a successful CTA/IND filing. Citryll aims to start the CIT-013 clinical studies in two years.
“Citryll is at an exciting time in their development program and we will be supporting them to help ensure they are fully prepared for a first in human clinical trial of their new therapy. Early-stage companies are an important part of our business and we have the tools and technologies to help de-risk their candidate. Ensuring solutions for the lifecycle of their product together with business models in sync with their funding all contribute to reducing the risks for growing companies.” Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza said.
NETosis is the formation of neutrophil extracellular traps, a recently discovered function of neutrophils, part of the innate immune system. Citryll’s lead programme, targets the formation of NETs and its pathological consequences. More info here
Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found atlonza.com
Citryll Contact Details
|Dr. Helmuth van Es CEO firstname.lastname@example.org +33 621684888|
Lonza Contact Details
| Dr. Kristin Koehler|
Investor Relations Tel +41 61 316 8782 Kristin.email@example.com
|Dr. Sanna Fowler|
Head of External Communications Tel +41 61 316 8929 Sanna.firstname.lastname@example.org
Lonza Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.